CA2793643A1 - Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media - Google Patents

Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media Download PDF

Info

Publication number
CA2793643A1
CA2793643A1 CA2793643A CA2793643A CA2793643A1 CA 2793643 A1 CA2793643 A1 CA 2793643A1 CA 2793643 A CA2793643 A CA 2793643A CA 2793643 A CA2793643 A CA 2793643A CA 2793643 A1 CA2793643 A1 CA 2793643A1
Authority
CA
Canada
Prior art keywords
vegf
jbo
hif
otitis media
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2793643A
Other languages
English (en)
French (fr)
Inventor
Michael T Cheeseman
Steve D. M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CA2793643A1 publication Critical patent/CA2793643A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2793643A 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media Abandoned CA2793643A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1004761.1 2010-03-22
GBGB1004761.1A GB201004761D0 (en) 2010-03-22 2010-03-22 Method
PCT/GB2011/000382 WO2011117568A1 (en) 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Publications (1)

Publication Number Publication Date
CA2793643A1 true CA2793643A1 (en) 2011-09-29

Family

ID=42228117

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2793643A Abandoned CA2793643A1 (en) 2010-03-22 2011-03-18 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media

Country Status (8)

Country Link
US (1) US20130078260A1 (zh)
EP (1) EP2549989A1 (zh)
JP (1) JP2013522350A (zh)
CN (1) CN102905697A (zh)
AU (1) AU2011231405A1 (zh)
CA (1) CA2793643A1 (zh)
GB (1) GB201004761D0 (zh)
WO (1) WO2011117568A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073647A2 (en) * 2014-11-04 2016-05-12 University Of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
EA202091509A1 (ru) 2017-12-19 2020-09-22 Акуос, Инк. Aav-опосредованная доставка терапевтических антител во внутреннее ухо
CN112807293B (zh) * 2021-03-01 2023-06-02 青岛大学 甲磺酸去铁胺在制备治疗中耳炎药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
WO2008094208A2 (en) * 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics

Also Published As

Publication number Publication date
CN102905697A (zh) 2013-01-30
US20130078260A1 (en) 2013-03-28
WO2011117568A1 (en) 2011-09-29
JP2013522350A (ja) 2013-06-13
GB201004761D0 (en) 2010-05-05
EP2549989A1 (en) 2013-01-30
AU2011231405A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
Gao et al. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis
de Almeida et al. The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease
Zhang et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer
Fu et al. Pim‐1 as a therapeutic target in lupus nephritis
Tawara et al. HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β
Natsumeda et al. Targeting notch signaling and autophagy increases cytotoxicity in glioblastoma neurospheres
JP6502863B2 (ja) 結腸直腸癌を処置する方法
Liu et al. Inhibition of autophagy by chloroquine enhances the antitumor efficacy of sorafenib in glioblastoma
US20170285005A1 (en) Rac1 inhibitors for the treatment of alport glomerular disease
Denning et al. C23, an oligopeptide derived from cold-inducible RNA-binding protein, suppresses inflammation and reduces lung injury in neonatal sepsis
Zhang et al. A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes
Yemchenko et al. PPAR-gamma agonist pioglitazone reduced CD68+ but not CD163+ macrophage dermal infiltration in obese psoriatic patients
US20130078260A1 (en) Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media
Han et al. TMP195 exerts antitumor effects on colorectal cancer by promoting M1 macrophages polarization
US10695341B2 (en) Compositions and methods for treating endometriosis
US20230158057A1 (en) Compositions and methods for the treatment of pain
Ma et al. IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammation
Chen et al. The down-regulation of XBP1, an unfolded protein response effector, promotes acute kidney injury to chronic kidney disease transition
US11357780B2 (en) Methods and compositions relating to the inhibition of IP6K1
WO2021081580A1 (en) Treatment of renal cystic disease
Hua et al. β-arrestin1 regulates astrocytic reactivity via Drp1-dependent mitochondrial fission: implications in postoperative delirium
WO2020212484A1 (en) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
Ipinmoroti et al. Selective pharmacological inhibition alters human carcinoma lung cell-derived extracellular vesicle formation
US20240165078A1 (en) Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphorylation in cancer
WO2024099346A1 (zh) 吲唑类化合物在治疗炎症小体激活介导的疾病中的应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160318